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INTRODUCTION
As the novel coronavirus (SARS-CoV-2) pandemic continues to spread, some predict a
disproportionate toll on low- and middle-income countries (LMICs), as it stresses already
under-resourced health systems in densely populated regions (1). Two LMICs, Brazil and India, are
among the top three countries by number of confirmed COVID-19 cases (2). While the reported
prevalence of COVID-19 in sub-Saharan Africa is currently lower than reports from Asia, North
America, and Europe, epidemiological modeling suggests that nearly a quarter of a billion people
in sub-Saharan Africa may contract SARS-CoV-2 in the first year of the pandemic (3). The UN
estimates up to 3 million COVID-19-related deaths in the region (4). Furthermore, the spread of
SARS-CoV-2 in LMICs threatens to further increase the burden of adverse birth outcomes among
the majority of global pregnancies.
Globally, there are over 213 million pregnancies every year, of which an estimated 190 million
(89%) occur in low resource settings where the risk of poor birth outcomes is highest (5). The
contributing risk factors for these adverse outcomes are multifactorial: pregnant women in LMICs
struggle to access antenatal care (6); an estimated 1 in 10 women in LMICs do not receive adequate
nutrition in pregnancy (7); and the majority of pregnant women at risk of, or living with, malaria,
HIV, and/or tuberculosis (TB) reside in LMICs (8, 9). High rates of these and other co-morbidities
in pregnancy directly translate to adverse birth outcomes: more than 60% of children that are born
preterm each year are born in sub-Saharan Africa and south Asia (e.g., India alone accounts for
23.6% of total global preterm births), accounting for over 750,000 deaths within the first month of
life (Figure 1) (10).
COVID-19 is likely to influence maternal-child health in profound ways, from the physiological
impact of the disease itself, to its indirect impacts on health systems, social, economic, and
cultural structures, and by exacerbating pre-existing gender and healthcare access inequalities.
Research is needed to identify the risks of COVID-19 in pregnancy, and its interplay with highly
prevalent comorbidities already concentrated in LMICs including malnutrition, anemia, HIV, TB,
andmalaria. Identification andmitigation of both infectious and response-related barriers to health
access and information for pregnant women during pandemics is essential for protecting the health
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FIGURE 1 | Infographic depicting inequalities in pregnancy outcomes and access to antenatal care at baseline and during a pandemic. Low- and middle-income
countries (LMICs); preterm birth (PTB). Data sources (5–7, 9–13).
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of women and their children. Despite the current international
focus on COVID-19, there remains an urgent need to direct
research attention and resources to the impact of emerging
infectious disease threats such as COVID-19 on pregnant women
in LMICs.
EVIDENCE OF THE IMPACT OF
RESPIRATORY INFECTION IN
PREGNANCY
Very little information is currently available on the impact of
COVID-19 in pregnancy. The first joint report published by the
WHO and the Chinese Government mentions pregnancy twice
in 40 pages (14). Much of the currently published literature
contains conflicting information drawn from case reports and
case-series with very small sample sizes. Although several original
studies and systematic reviews suggest pregnant women are not
at increased risk of severe clinical outcomes and that there is
low risk of vertical transmission (15–19), one study reported
seven maternal deaths out of nine cases in their multi-site
COVID-19 case series (20). Increased rates of preterm birth
and cesarean-section have also been reported (19, 21, 22). Due
to the timing of the COVID-19 outbreak, most studies have
reported on infection during the third trimester and there is
little to no evidence of its impact in early pregnancy. Based on
outcomes of pregnancies complicated by other severe respiratory
infections, we hypothesize that more rigorous, pregnancy-
focused research will reveal that pregnant women face an
increased risk of poor clinical and birth outcomes during this
COVID-19 pandemic.
Pregnant women have a higher risk of viral respiratory
infection and are more likely to experience severe clinical
symptoms (23). Both pandemic (e.g., H1N1) and seasonal
influenza in pregnancy have been linked to severe maternal
morbidity and increased risk of fetal death and preterm birth
(24, 25). Pneumonia is also associated with increased risk of
maternal morbidity, mortality, and poor birth outcomes. Co-
existing maternal disease increases both the risk of infection as
well as the risk of poor clinical outcomes (26). Therefore, as the
COVID-19 pandemic continues, overlap with seasonal influenza
and resulting co-infections will likely exacerbate morbidity and
mortality in pregnancy. A rapidly growing body of evidence
further indicates that infections during pregnancy, including
respiratory infections such as influenza, are associated with
increased risk of neurocognitive and neuropsychiatric disorders
in exposed offspring (27). A review and a meta-analysis of
coronavirus-spectrum infections reported increased preterm
birth, miscarriage, preeclampsia, cesarean-section, and perinatal
death in pregnant women with SARS, MERS, or COVID-19
(28, 29). However, the majority of data on coronavirus spectrum
infections has been from Europe and North America. In LMICs,
there is very little investigation into the impact of coronavirus
infections on pregnancy despite the high prevalence of co-
existing maternal conditions or co-infections, and barriers to
quality antenatal care.
INCREASED RISK FOR WOMEN IN LOW-
AND MIDDLE-INCOME COUNTRIES
During pregnancy, women’s attendance at routine antenatal
care visits results in high rates of exposure to health care
environments. Consequently, women who continue to observe
the recommended antenatal guidelines will be at increased
risk for exposure to SARS-CoV-2. Furthermore, as health
care systems become over-burdened by COVID-19, access and
adherence to prenatal and obstetric care, as well as the quality
of care, will suffer. Without timely intervention, pandemic-
related restrictions on movement, reduced access to care, and
economic constraints could lead to the reversal of important
gains made in global antenatal care and maternal-child health.
The 2014 Ebola outbreak in west-Africa provides a stark
warning of the effect an infectious outbreak may have on
already weak maternal-child health systems (11, 30). In Liberia,
access to antenatal care plummeted by 50% and healthcare
facility-based deliveries were reduced by 35% during the Ebola
outbreak (11). Similar declines were also reported in Guinea,
and by publication in 2017, had still not recovered to pre-
outbreak levels (30). Preliminary evidence from both Uganda
and Nepal indicates that even without a high COVID-19 burden,
pandemic-related restrictions have already begun to impact
maternal-child outcomes in LMICs, showing sharp declines in
maternal facility deliveries (by 50% in Nepal), and increased
maternal and neonatal mortality (31, 32). Although maternal-
child outcomes with Ebola virus infection in pregnancy are
more severe than existing evidence suggests for SARS-CoV-2
infection, these studies indicate immediate and lasting effects
of emergent infectious diseases on vulnerable maternal-child
healthcare systems in LMICs, and highlight the need for research
and support to address this issue during the current COVID-
19 pandemic.
The prevalence of medically complicated pregnancies is high
among women living in LMICs. Women in LMICs carry a
higher risk of infection with HIV, malaria, and/or tuberculosis
compared to populations in high-income countries. Women
of reproductive age in these regions are also more likely
to have sickle cell disease, cardiac conditions (for example,
rheumatic heart disease), and COPD due to indoor air pollution
(33), conditions that increase the risk of developing severe
COVID-19 (34). Furthermore, pregnant women in LMICs
are at increased risk of having undiagnosed and/or sub-
optimally managed gestational hypertension, pre-eclampsia,
and gestational diabetes (35, 36). Hypertensive disorders and
diabetes are both associated with an increased risk of severe
COVID-19 in non-pregnant populations (34), but their impact
on COVID-19 severity in pregnant women is not known.
Furthermore, emerging data indicates the potential for long-
lasting unintended consequences of governmental COVID-19
responses and COVID-19 related interruptions to maternal-
child health interventions and critical public health programs
(e.g., TB, HIV, and malaria diagnosis and treatment programs;
nutritional interventions) on maternal morbidity and mortality
in LMICs (32, 37, 38). The interplay of decreased health
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care access, increased prevalence of medical comorbidities,
and the impact of SARS-CoV-2 exposure on pregnancy
outcomes in LMICs warrants close surveillance and study
in order to guide public health policies in the most at-
risk regions.
Beyond antenatal care, pregnant and perinatal women will
face psychosocial challenges related to stigma and/or social
isolation, a lack of information or misinformation concerning
neonatal care (e.g., appropriateness of breastfeeding with SARS-
CoV-2 infection or suspected infection), and lack of or reluctance
to access facility-based neonatal care services (e.g., for routine
immunizations). Countries with strict restrictions on movement
(e.g., banning public and private transport, curfews) have
seen an impact on the ability of pregnant women to seek
routine and/or emergency care, as well as increases in food
insecurity and sexual and gender-based violence (32, 39).
Challenges to providing antenatal and neonatal care during the
COVID-19 outbreak will be further compounded if pregnant
women and primary caregivers do not have access to up-to-
date and accurate public health messaging to understand risks
and recommendations.
Access to contraceptives is often limited in LMICs including
sub-Saharan Africa and south Asia and the COVID-19 outbreak
is likely to both disrupt global supply chains and prevent women
from accessing providers of contraception. Many women will
be isolated in domestic environments where they may not
have input into family planning (Figure 1). Lessons from the
Ebola crisis of 2014 indicate that widespread school closures
will disproportionately affect girls of reproductive age, and lead
to increased rates of sexual exploitation, sexual and gender-
based violence, and forced marriage (39, 40). Compromising
the sexual and reproductive health of women and girls means
many are likely to experience pregnancy during the COVID-
19 pandemic. Modeling estimates published by the Guttmacher
Institute suggest that a 10% reduction in short and long-
term contraceptive use could result in more than 15 million
unintended pregnancies across 132 LMICs (41). As a result
of gender inequality, the impact of a pandemic on sexual
and reproductive health often goes unnoticed and unaddressed
(12). Efforts to provide the means for pregnant women to
safely access healthcare and healthcare providers are critical,
as are efforts for widespread dissemination of public health
policy and recommendations regarding other critical aspects
of pregnancy (e.g., breastfeeding, immunization). Public and
private health systems should craft responses to COVID-19
that address barriers to access and sexual and reproductive
health outcomes in LMICs, in ways that protect the immediate
health of pregnant women and inform future pandemic
preparedness measures.
PREGNANT WOMEN DESERVE THE
BENEFITS OF DRUG AND VACCINE
THERAPY
Pregnant women are almost uniformly excluded from clinical
trials. Protecting vulnerable populations from risks associated
with experimental therapies is essential and particularly
important in LMICs where limited access to high-quality care
creates additional vulnerabilities. However, the most at-risk
populations also deserve to benefit from therapeutics that
may improve outcomes. Many of the drugs being proposed
for the treatment or chemoprophylaxis of COVID-19 have
evidence-based safety profiles for use in pregnancy including
lopinavir/ritonavir, remdesivir, and hydroxychloroquine
(42–45). Yet, large government-funded clinical trials for
treatment of COVID-19 (e.g., NIH-funded trials [NCT04280705,
NCT04332991]) continue to list pregnancy as an exclusion
criterion (46). The WHO Solidarity Trial [ISRCTN83971151]
originally listed pregnancy in its exclusion criteria but has
since removed it. As the WHO seems to have done, the
ethics of excluding women from trials where they may benefit
from treatments known to be safe in pregnancy needs to
be carefully considered. During the 2013–2016 west-Africa
Ebola outbreak, where mortality rates for pregnant women
and their unborn children approached 100%, women were
actively excluded from clinical trials of novel therapeutics
(13). Pregnant women could not participate in clinical
trials in the face of a life-threatening infection for which
pregnancy increased their risk. This highlights the importance
of understanding the unique impact of COVID-19 on pregnancy
to assess the risk and benefits associated with novel treatments
and vaccines.
As novel treatments and vaccines are developed and
employed, we must consider why pregnant women continue
to be excluded from trials by default, and when it is or is
not appropriate to include them. Given the immediacy of the
COVID-19 pandemic and the complexity of pharmacokinetics
and pharmacodynamics in pregnancy, studies with therapies
already known to be safe in pregnancy should be prioritized. To
globally maximize benefits and health equity for pregnant
and perinatal women, novel treatments should also be
accessible to women living in the regions where most
pregnancies occur (e.g., LMICs). These treatments should
be effective, inexpensive, and easily accessible. Moreover,
studies should also examine the impact of co-morbidities on
therapeutic outcomes, including co-infection with HIV, malaria,
and TB.
CONCLUSIONS
As the global implications of the COVID-19 outbreak in LMICs
begin to emerge, it is becoming increasingly clear that vulnerable
populations will carry a disproportionate burden. Pregnant
women in LMICs can face enormous obstacles to healthy birth
outcomes for themselves and their unborn and newborn children
and these barriers increase in the face of a global pandemic.
As public health systems and the international medical research
community focus resources on understanding COVID-19 and
identifying therapeutics, the impact of infection in pregnancy
and the unique health needs of pregnant women during a
pandemic should not be neglected or passed over to be studied
retrospectively. Pregnant women, including those in LMICs,
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deserve an immediate and enhanced focus during the COVID-19
outbreak to protect every woman and every child.
AUTHOR CONTRIBUTIONS
CM and KK: project conception, and oversight. CM, AW, JW,
KK, and AC: research, analysis, writing, and editing. All authors:
read and approved the final manuscript.
FUNDING
This work was supported by the Canadian Institutes of
Health Research (CIHR FDN-148439 to KK), Canada Research
Chair (KK), CIHR Doctoral Award GSD-157907 (AW), CIHR
Vanier Canada Award (JW), Eliot Phillipson Clinician-Scientist
Training Program (JW), and Open Philanthropy. The funders
had no role in researching or writing the report, or the decision
to submit the article for publication.
REFERENCES
1. Massinga Loembe M, Tshangela A, Salyer SJ, Varma JK, Ouma AEO,
Nkengasong JN. COVID-19 in Africa: the spread and response. Nat Med.
(2020) 26:999–1003. doi: 10.1038/s41591-020-0961-x
2. World Health Organization. Coronavirus Disease (COVID-19) Dashboard.
(2020). https://covid19.who.int/ (accessed August 11, 2020).
3. Cabore JW, Karamagi HC, Kipruto H, Asamani JA, Droti B, Seydi
ABW, et al. The potential effects of widespread community transmission
of SARS-CoV-2 infection in the World Health Organization African
Region: a predictive model. BMJ Global Health. (2020) 5:e002647.
doi: 10.1136/ bmjgh-2020-002647
4. United Nations Economic Commission for Africa. COVID-19 in Africa:
Protecting Lives and Economies. (2020). Available online at: https://www.
uneca.org/sites/default/files/PublicationFiles/eca_covid_report_en_24apr_
web1.pdf (accessed May 7, 2020).
5. Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies
worldwide in 2012 and recent trends. Stud Fam Plann. (2014) 45:301–14.
doi: 10.1111/j.1728-4465.2014.00393.x
6. Arsenault C, Jordan K, Lee D, Dinsa G, Manzi F, Marchant T, et al. Equity in
antenatal care quality: an analysis of 91 national household surveys. Lancet
Glob Health. (2018) 6:e1186–95. doi: 10.1016/S2214-109X(18)30389-9
7. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis
M, et al. Maternal and child undernutrition and overweight in low-
income and middle-income countries. Lancet. (2013) 382:427–51.
doi: 10.1016/S0140-6736(13)60937-X
8. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: an
estimate of the global burden of disease. Lancet Glob Health. (2014) 2:e710–6.
doi: 10.1016/S2214-109X(14)70330-4
9. UNAIDS. Women and HIV: A Spotlight on Adolescent Girls and Young
Women. (2019). Available online at: https://www.unaids.org/sites/default/
files/media_asset/2019_women-and-hiv_en.pdf (accessed May 7, 2020).
10. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal
R, et al. National, regional, and worldwide estimates of preterm birth
rates in the year 2010 with time trends since 1990 for selected
countries: a systematic analysis and implications. Lancet. (2012) 379:2162–72.
doi: 10.1016/S0140-6736(12)60820-4
11. Shannon FQ 2nd, Horace-Kwemi E, Najjemba R, Owiti P, Edwards J,
Shringarpure K, et al. Effects of the 2014 Ebola outbreak on antenatal care
and delivery outcomes in Liberia: a nationwide analysis. Public Health Action.
(2017) 7:S88–S93. doi: 10.5588/pha.16.0099
12. Camara BS, Delamou A, Diro E, Beavogui AH, Ayadi AME, Sidibe S, et al.
Effect of the 2014/2015 Ebola outbreak on reproductive health services in
rural district of Guinea: an ecological study. Trans R Soc TropMedHyg. (2017)
111:22–9. doi: 10.1093/trstmh/trx009
13. Gomes MF, de la Fuente-Nunez V, Saxena A, Kuesel AC. Protected to death:
systematic exclusion of pregnant women from Ebola virus disease trials.
Reprod Health. (2017) 14:172. doi: 10.1186/s12978-017-0430-2
14. WHO-China Joint Mission on COVID-19. Report of the WHO-China Joint
Mission on Coronavirus Disease 2019 (COVID-19). (2019). Available online
at: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-
mission-on-covid-19-final-report.pdf (accessed May 7, 2020).
15. Elshafeey F, Magdi R, Hindi N, Elshebiny M, Farrag N, Mahdy S, et al. A
systematic scoping review of COVID-19 during pregnancy and childbirth. Int
J Gynaecol Obstet. (2020) 150:47–52. doi: 10.1002/ijgo.13182
16. Ferrazzi E, Frigerio L, Savasi V, Vergani P, Prefumo F, Barresi S,
et al. Vaginal delivery in SARS-CoV-2 infected pregnant women in
Northern Italy: a retrospective analysis. BJOG. (2020) 127:1116–21.
doi: 10.1111/1471-0528.16278
17. Qiancheng X, Jian S, Lingling P, Lei H, Xiaogan J, Weihua L, et al.
Coronavirus disease 2019 in pregnancy. Int J Infect Dis. (2020) 95:376–83.
doi: 10.1016/j.ijid.2020.04.065
18. Yan J, Guo J, Fan C, Juan J, Yu X, Li J, et al. Coronavirus disease 2019 in
pregnant women: a report based on 116 cases. Am J Obstet Gynecol. (2020)
223:111.e1–111.e14 doi: 10.1016/j.ajog.2020.04.014
19. Yang Z, Wang M, Zhu Z, Liu Y. Coronavirus disease 2019 (COVID-19)
and pregnancy: a systematic review. J Matern Fetal Neonatal Med. (2020).
doi: 10.1080/14767058.2020.1759541. [Epub ahead of print].
20. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, Seferovic MD, Aski SK, Arian
SE, et al. Maternal death due to COVID-19 disease. Am J Obstet Gynecol.
(2020) 223:109.e1–109.e16. doi: 10.1016/j.ajog.2020.04.030
21. Della Gatta AN, Rizzo R, Pilu G, Simonazzi G. COVID19 during pregnancy:
a systematic review of reported cases. Am J Obstet Gynecol. (2020) 223:36–41.
doi: 10.1016/j.ajog.2020.04.013
22. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-
19: a systematic review of 108 pregnancies. Acta Obstet Gynecol Scand. (2020)
99:823–9. doi: 10.1111/aogs.13867
23. Liu H, Wang LL, Zhao SJ, Kwak-Kim J, Mor G, Liao AH. Why are pregnant
women susceptible to COVID-19? An immunological viewpoint. J Repord
Immunol. (2020) 139:103122. doi: 10.1016/j.jri.2020.103122
24. Fell DB, Savitz DA, Kramer MS, Gessner BD, Katz MA, Knight M, et al.
Maternal influenza and birth outcomes: systematic review of comparative
studies. BJOG. (2017) 124:48–59. doi: 10.1111/1471-0528.14143
25. Regan AK, Feldman B, Azziz-Baumgartner E, Naleway AL, Williams J, Wyant
BE, et al. An international cohort study of birth outcomes associated with
hospitalized acute respiratory infection during pregnancy. J Infect. (2020)
81:48–56. doi: 10.1016/j.jinf.2020.03.057
26. Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit Care Med.
(2005) 33:S390–7. doi: 10.1097/01.ccm.0000182483.24836.66
27. Kepinska AP, Iyegbe CO, Vernon AC, Yolken R, Murray RM, Pollak TA.
Schizophrenia and influenza at the centenary of the 1918-1919 Spanish
influenza pandemic: mechanisms of psychosis risk. Front Psychiatry. (2020)
11:72. doi: 10.3389/fpsyt.2020.00072
28. Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, et al.
Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19)
during pregnancy: a systematic review andmeta-analysis.Am J Obstet Gynecol
MFM. (2020) 2:100107. doi: 10.1016/j.ajogmf.2020.100107
29. Rasmussen SA, Smulian JC, Lednicky JA, Wen TS, Jamieson DJ. Coronovirus
disease 2019 (COVID-19) and pregnancy: what obstetricians need to know.
Am J Obstet Gynecol. (2020) 222:415–26. doi: 10.1016/j.ajog.2020.02.017
30. Delamou A, Ayadi AME, Sidibe S, Delvaux T, Camara BS, Sandouno SD,
et al. Effect of Ebola virus disease on maternal and child health services in
Guinea: a retrospective observational cohort study. Lancet Glob Health. (2017)
5:e448–e3457. doi: 10.1016/S2214-109X(17)30078-5
Frontiers in Global Women’s Health | www.frontiersin.org 5 September 2020 | Volume 1 | Article 564560
McDonald et al. Pregnancy in LMIC During COVID-19
31. Ashisk KC, Gurung R, Kinney MV, Sunny AK, Moinuddin M, Basnet O, et al.
Effect of the COVID-19 pandemic response on intrapartum care, stillbirth,
and neonatal mortality outcomes in Nepal: a prospective observational study.
Lancet Glob Health. (2020). doi: 10.1016/S2214-109X(20)30345-4. [Epub
ahead of print].
32. Bell D, Hansen KS, Kiragga AN, Kambugu A, Kissa J, Mbonye AK. Predicting
the impact of COVID-19 and the potential impact of the public health
response on disease burden in Uganda. Am J Trop Med Hyg. (2020) 103:1191–
7. doi: 10.4269/ajtmh.20-0546
33. Amegah AK, Quansah R, Jaakkola JJK. Household air pollution from solid
fuel use and risk of adverse pregnancy outcomes: a systematic review
and meta-analysis of the empirical evidence. PLoS ONE. (2014) 9:e113920.
doi: 10.1371/journal.pone.0113920
34. Centers for Disease Control and Prevention. Coronavirus Disease 2019
(COVID-19). (2020). Available online at: https://www.cdc.gov/coronavirus/
2019-ncov/need-extra-precautions/people-with-medical-conditions.html
(accessed August 11, 2020).
35. Goldenberg RL, McClure EM, Harrison MS, Miodovnik M. Diabetes during
pregnancy in low- and middle-income countries. Am J Perinatol. (2016)
33:1227–35. doi: 10.1055/s-0036-1584152
36. Warren CE, Hossain SMI, Ishaku S, Armbruster D, Hillman E. A
primary health care model for managing pre-eclampsia and eclampsia
in low- and middle-income countries. Reprod Health. (2020) 17:46.
doi: 10.1186/s12978-020-0897-0
37. Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker
C, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis,
and malaria in low-income and middle-income countries: a modelling
study. Lancet Glob Health. (2020) 8:e1132–41. doi: 10.1016/S2214-109X(20)3
0288-6
38. Roberton T, Carter ED, Chou VB, Stegmuller AR, Jackson BD, Tam
Y, et al. Early estimates of the indirect effects of the COVID-19
pandemic on maternal and child mortality in low-income and middle-
income countries: a modelling study. Lancet Glob Health. (2020) 8:e901–8.
doi: 10.1016/S2214-109X(20)30229-1
39. Johnson K, Green L, Volpellier M, Kidenda S, McHale T, Naimer K,
et al. The impact of COVID-19 on services for people affected by
sexual and gender-based violence. Int J Gynaecol Obstet. (2020) 150:285–7.
doi: 10.1002/ijgo.13285
40. UNESCO. COVID-19 School Closures Around the World Will Hit Girls
Hardest. (2020). Available online at: https://en.unesco.org/news/covid-19-
school-closures-around-world-will-hit-girls-hardest (accessed August 11,
2020).
41. Riley T, Sully E, Ahmed Z, Biddlecom A. Estimates of the potential impact
of the COVID-19 pandemic on sexual and reproductive health in low- and
middle-income countries. Int Perspect Sex Reprod Health. (2020) 46:73–6.
doi: 10.1363/46e9020
42. Cohan D, Natureeba P, Koss CA, Plenty A, Luwedde F, Mwesigwa J, et al.
Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral
therapy in HIV-infected pregnant Ugandan women. AIDS. (2015) 29:183–91.
doi: 10.1097/QAD.0000000000000531
43. Kaplan YC, Ozsarfati J, Nickel C, Koren G. Reproductive outcomes following
hydroxychloroquine use for autoimmune diseases: a systematic review and
meta-analysis. Br J Clin Pharmacol. (2016) 81:835–48. doi: 10.1111/bcp.12872
44. PREVAIL II Writing Group, Multi-National PREVAIL II Study Team, Davy
RT Jr, Dodd L, Proschan MA, Neaton J, et al. A randomized, controlled
trial of ZMapp for Ebola virus infection. N Engl J Med. (2016) 375:1448–56.
doi: 10.1056/NEJMoa1604330
45. LaCourse SM, John-Stewart G, Adams Waldorf KM. Importance of inclusion
of pregnant and breastfeeding women in COVID-19 therapeutic trials. Clin
Infect Dis. (2020) 71:879–81. doi: 10.1093/cid/ciaa444
46. Costantine MM, Landon MB, Saade GR. Protection by exclusion: another
missed opportunity to include pregnant women in research during the
Coronavirus Disease 2019 (COVID-19) pandemic. Obstet Gynecol. (2020)
136:26–8. doi: 10.1097/AOG.0000000000003924
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 McDonald, Weckman, Wright, Conroy and Kain. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Global Women’s Health | www.frontiersin.org 6 September 2020 | Volume 1 | Article 564560
